# Maxime Pesant

> Maxime Pesant is a Series B investor at GeneChem backing Biotechnology and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [GeneChem](https://shizune.co/investors/profile/genechem)
- Location: Westmount, Canada
- Total investments: 3
- Last investment: Sep 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/maximepesant/

Maxime Pesant is a Series B investor at GeneChem in Westmount focused on Biotechnology and Therapeutics. M. Pesant joined the team subsequently to the closing of AgeChem. Previously, he worked for GeneChem as a consultant and spent two years at CDP Capital Technologies – Biotechnologies as a Junior Analyst. He also held positions of Financial Analyst for various small businesses. M. Pesant received a Bachelor in Business Administration from HECMontreal in 2004 and is a member of the Ordre des CPA du Québec. He is also a CFA charterholder.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Oligon | Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email. | $14M |  | Sep 23, 2025 |  |
| KisoJi Biotechnology | KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. | $40.6M | Series B | Dec 02, 2024 |  |
| Feldan Therapeutics | Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $21M | Series B | Sep 04, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Investissement Quebec](https://shizune.co/investors/profile/investissement-quebec) — VC Fund, 2 deals together
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 1 deal together
- [CTI Life Sciences Fund](https://shizune.co/investors/profile/cti-life-sciences-fund-2) — VC Fund, 1 deal together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 1 deal together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 1 deal together
- [Remiges Ventures](https://shizune.co/investors/profile/remiges-ventures) — VC Fund, 1 deal together

## About GeneChem

VC Fund · Montréal, Canada

GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem Therapeutics Venture Fund L.P.. With committed capital of $136.5 million, the Therapeutics Fund's objectives were to invest within the genomics industry but specifically in companies developing therapeutics forproliferative disorders including cancer, infectious diseases, inflammation and diabetes.

5 contacts available at GeneChem.

| Name | Title | Profile |
| --- | --- | --- |
| Elizabeth Douville | General Partner | https://shizune.co/investors/profile/lizabeth-douville |
| Maxime Pesant | Vice-President, Finance | https://shizune.co/investors/profile/maxime-pesant |
| Fabienne Perreau | Administrative Assistant | https://shizune.co/investors/profile/fabienne-perreau |
| Inès Holzbaur | General Partner | https://shizune.co/investors/profile/ins-holzbaur |
| John Clement | General Partner | https://shizune.co/investors/profile/john-clement |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Maxime Pesant invest in?

Maxime Pesant invests primarily in Biotechnology and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Maxime Pesant last invest?

The most recent investment recorded for Maxime Pesant closed in Sep 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co